Trial Profile
A study to examine cerebrospinal fluid transitivity and efficacy of afatinib in carcinomatous meningitis patients with non-small cell lung cancer patients harboring EGFR mutation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Aug 2017
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Meningeal carcinomatosis; Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Aug 2017 Status changed from active, no longer recruiting to completed.
- 01 Aug 2017 Results published in the Anticancer Research
- 01 Aug 2017 Status changed from recruiting to active, no longer recruiting as per results published in the Anticancer Research.